» Articles » PMID: 33244562

Evaluation of the Efficacy of Probiotics (MCP® BCMC® Strains) Treating Constipation in Elderly Patients with Multiple Chronic Co-Morbidities: A Randomized Control Trial

Overview
Date 2020 Nov 27
PMID 33244562
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate the impact of a microbial cell preparation (MCP®) (Hexbio®; comprising MCP® BCMC® strains) on stool frequency, consistency, and constipation-related symptoms in elderly patients with multiple chronic medical conditions.

Design: Randomised control trial.

Setting: Medical outpatient and medical/surgical in-patient unit in single tertiary center.

Participant: Patients aged ≥ 60 years who experience constipation and have multiple chronic medical conditions.

Methods: Participants with constipation were blindly randomized into either a treatment (MCP® BCMC® strains) or a placebo group. The treatment was administered twice daily.

Measurement: Gastrointestinal symptoms and stool habits were assessed over a week during the intervention via the use of a questionnaire and stool diary.

Results: Stool frequency was seen to be higher and the improvement in stool consistency was more significant in the treatment group than in the placebo group (p =<0.001). A significant improvement in symptoms was demonstrated in patients who received MCP® BCMC® strains,specifically with respect to straining (p = < 0.001) and a sensation of incomplete evacuation (p = < 0.001). reduction in anorectal blockage symptoms and the need for manual stool evacuation was also demonstrated, but this finding was not statistically significant. Significant adverse events were not observed.

Conclusions: An improvement in stool frequency and consistency was reported in elderly patients with chronic medical conditions following the administration of MCP® BCMC® strains.

Citing Articles

Effects of probiotics on selected anthropometrics and biochemical measures in overweight or obese Saudi subjects: a double-blind, placebo-controlled, randomised clinical trial.

AlMalki S, Alfawaz H, Binmoammar T, AlBahlei S, Al Bakr L, Alzahrani A Public Health Nutr. 2024; 27(1):e225.

PMID: 39501805 PMC: 11645120. DOI: 10.1017/S1368980024002003.


2022 Seoul Consensus on Clinical Practice Guidelines for Functional Constipation.

Cho Y, Lee Y, Shin J, Jung H, Park S, Kang S J Neurogastroenterol Motil. 2023; 29(3):271-305.

PMID: 37417257 PMC: 10334201. DOI: 10.5056/jnm23066.


The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease.

Ayob N, Muhammad Nawawi K, Mohamad Nor M, Ali R, Ahmad H, Oon S Biomedicines. 2023; 11(2).

PMID: 36831176 PMC: 9953317. DOI: 10.3390/biomedicines11020640.


Effect of Paroxetine Combined with Probiotics in Patients with Type 2 Diabetes Mellitus Complicated with Gastrointestinal Dysfunction and Liver Cancer.

Peng Y, Yang X, Wang Y J Oncol. 2021; 2021:4529915.

PMID: 34659410 PMC: 8516543. DOI: 10.1155/2021/4529915.